← Eichor
Condition: Non Muscle Invasive Bladder Cancer Nmibc Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Non Muscle Invasive Bladder Cancer Nmibc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
Phase N/A · 6 location(s) · University of Washington · NCT07225127To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients Wi
Phase 1/Phase 2 · 6 location(s) · RemeGen Co., Ltd. · NCT06378242Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study
NA · 1 location(s) · University of Aarhus · NCT07339761Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Pa
Phase 2 · 16 location(s) · Theralase® Technologies Inc. · NCT03945162Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
Phase 1/Phase 2 · 59 location(s) · Janssen Research & Development, LLC · NCT05316155A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unr
Phase 3 · 2 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07424287A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Pati
NA · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07036731Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder
Phase 2 · 71 location(s) · Protara Therapeutics · NCT05951179Blue Light Cystoscopy With Cysview® Registry
Phase N/A · 23 location(s) · Photocure · NCT02660645Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Blad
Phase 2 · 46 location(s) · Tyra Biosciences, Inc · NCT06995677Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladde
Phase 2 · 1 location(s) · Shanxi Province Cancer Hospital · NCT07646145Safety and Efficacy of 9MW2821 in the Treatment of High-risk Non-muscle-invasive Bladder Cancer (NMIBC)
Phase 1 · 1 location(s) · The Affiliated Nanjing Drum Tower Hospital of Nanjing Univer · NCT06551233Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer
NA · 1 location(s) · Lahey Clinic · NCT07187063A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Phase 1 · 68 location(s) · Pfizer · NCT07206225A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC
Phase 1/Phase 2 · 1 location(s) · Shanghai Hengrui Pharmaceutical Co., Ltd. · NCT05410730The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non
Phase N/A · 2 location(s) · Tianjin Medical University Second Hospital · NCT07130578Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIB
Phase 3 · 3 location(s) · Shaogang Wang · NCT06696794Toripalimab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration
Phase 2 · 1 location(s) · Changhai Hospital · NCT07307456A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle
Phase 1 · 1 location(s) · Shanghai Hengrui Pharmaceutical Co., Ltd. · NCT06108492A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC
Phase 2 · 2 location(s) · ImmVira Pharma Co. Ltd · NCT06971614A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
Phase 1 · 17 location(s) · Aura Biosciences · NCT05483868Prognostic Effect of Whether Doing PLND During RC for High-risk NMIBC
NA · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05123625A Phase I Intravesical PPM Therapy for NMIBC
Phase 1 · 1 location(s) · VA Office of Research and Development · NCT05519241DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC
Phase 3 · 1 location(s) · Fudan University · NCT07207824A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC
Phase N/A · 13 location(s) · Janssen Research & Development, LLC · NCT07309445A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Phase 3 · 193 location(s) · Janssen Research & Development, LLC · NCT06319820A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (
Phase 1 · 3 location(s) · Ractigen Therapeutics. · NCT06351904A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer
Phase 1/Phase 2 · 12 location(s) · Suzhou Forlong Biotechnology Co., Ltd · NCT07122414Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Phase 2 · 65 location(s) · CG Oncology, Inc. · NCT06567743A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Phase 1/Phase 2 · 13 location(s) · Merck Sharp & Dohme LLC · NCT06637423
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.